JP2022500389A5 - - Google Patents

Info

Publication number
JP2022500389A5
JP2022500389A5 JP2021513344A JP2021513344A JP2022500389A5 JP 2022500389 A5 JP2022500389 A5 JP 2022500389A5 JP 2021513344 A JP2021513344 A JP 2021513344A JP 2021513344 A JP2021513344 A JP 2021513344A JP 2022500389 A5 JP2022500389 A5 JP 2022500389A5
Authority
JP
Japan
Prior art keywords
drug
seq
sequence
protein
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500389A (ja
JP7629394B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/074101 external-priority patent/WO2020053206A1/en
Publication of JP2022500389A publication Critical patent/JP2022500389A/ja
Publication of JP2022500389A5 publication Critical patent/JP2022500389A5/ja
Application granted granted Critical
Publication of JP7629394B2 publication Critical patent/JP7629394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513344A 2018-09-10 2019-09-10 リウマチ性疾患の治療に使用するためのコバーシン Active JP7629394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729068P 2018-09-10 2018-09-10
US62/729,068 2018-09-10
PCT/EP2019/074101 WO2020053206A1 (en) 2018-09-10 2019-09-10 Coversin for use in the treatment of rheumatic diseases

Publications (3)

Publication Number Publication Date
JP2022500389A JP2022500389A (ja) 2022-01-04
JP2022500389A5 true JP2022500389A5 (https=) 2022-09-09
JP7629394B2 JP7629394B2 (ja) 2025-02-13

Family

ID=67988965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513344A Active JP7629394B2 (ja) 2018-09-10 2019-09-10 リウマチ性疾患の治療に使用するためのコバーシン

Country Status (4)

Country Link
US (2) US20220047673A1 (https=)
EP (1) EP3849588A1 (https=)
JP (1) JP7629394B2 (https=)
WO (1) WO2020053206A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) * 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69534701T2 (de) * 1994-09-23 2006-10-19 Alexion Pharmaceuticals, Inc., Cheshire Verfahren zur behandlung von entzündlichen gelenkerkrankungen
EP1629098B1 (en) 2003-06-02 2009-04-01 Varleigh Limited Complement inhibitors from ticks
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
PL2061501T3 (pl) 2006-09-08 2016-01-29 Volution Immuno Pharmaceuticals Sa Sposób leczenia zaburzeń oddechowych
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
JP5840623B2 (ja) 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるｅｖ５７６
EP2978451B1 (en) * 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
WO2015127134A2 (en) * 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
US11730792B2 (en) * 2017-04-21 2023-08-22 Volution Immuno Pharmaceuticals Sa Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)

Similar Documents

Publication Publication Date Title
Pines et al. Cloning and expression of a rat brain L-glutamate transporter
US8318172B2 (en) Breaking immunological tolerance with a genetically encoded unnatural amino acid
Vivar et al. Advances in the treatment of rheumatoid arthritis
TWI701041B (zh) 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
JP2022500389A5 (https=)
JPH10500568A (ja) Ｔｎｆ／ｎｇｆスーパーファミリー受容体および可溶性オリゴマー ｔｎｆ／ｎｇｆスーパーファミリー受容体のモジュレーター
KR20250040096A (ko) Hbv 백신 및 hbv를 치료하는 방법
CN104684571A (zh) 新的il-17a结合分子及其医学应用
MXPA05012497A (es) Composiciones y metodos para el tratamiento del sindrome respiratorio agudo severo (sars).
KR20170120616A (ko) 염증성 질환의 치료 방법
US10507241B2 (en) Biomarkers useful in the treatment of IL-23A related diseases
Zhao et al. Research on liver damage caused by the treatment of rheumatoid arthritis with novel biological agents or targeted agents
TW416960B (en) Reshaped human antibody to human interleukin-8
Cavagna et al. The emerging role of biotechnological drugs in the treatment of gout
ES2253824T3 (es) Anticuerpos cataliticos y un metodo para producir los mismos.
EP1572065A2 (en) Method and pharmaceutical composition for the treatment of multiple sclerosis
US20230310409A1 (en) Treating rheumatoid arthritis
JP2023531944A5 (https=)
TWI465460B (zh) 用於治療病毒感染及癌症之新穎醫藥組合物
JP2022529266A5 (https=)
Sharma et al. Biologics in rheumatoid arthritis
WO2022051356A1 (en) Methods for treating disease and reducing drug-induced liver injury in patient populations
WO2012156811A2 (en) Compositions useful for the treatment of inflammatory disease or disorders
KR101625112B1 (ko) 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
JP7300008B2 (ja) 低免疫原性かつ低ＡＤＣＣ／ＣＤＣ機能の抗ＴＮＦ－αヒト化モノクローナル抗体ＴＣＸ０６０およびその使用